Thyroid hormone levels in children with Prader–Willi syndrome: a randomized controlled growth hormone trial and 10-year growth hormone study
Authors' conclusion
Our findings suggest that GH treatment decreases FT4 levels, due to increased peripheral conversion of FT4 to T3 in the first months of treatment, but thereafter, FT4 and T3 normalize and remain stable during long-term GH treatment in almost all children and adolescents with PWS.
Study context
- Population
- Children with Prader-Willi syndrome (PWS)2-year RCT
- Participants
- 49 children
- Comparison
- Growth hormone (GH) treatment vs control
- Primary endpoint
- Thyroid function (serum FT4, T3 and TSH) during GH treatment
Methodological details2-year randomized controlled GH trial, 10-year longitudinal GH study
- 2-year randomized controlled GH trial
- 10-year longitudinal GH study
Primary result
As reported in the abstract
FT4 SDS (RCT, GH group) · first 6 months
- GH: median (IQR) free T4 (FT4) standard deviation score (SDS) decreased from −0.84 (−1.07 to −0.62) to −1.32 (−1.57 to −1.08)
- P < .001
- GH: T3 SDS increased from 0.31 (−0.01-0.63) to 0.56 (0.32-0.79)
- P = .08
Further findings
FT4 SDS, 10-year GH study (n=240) · 2 to 10 years
- Median (IQR) FT4 SDS unchanged: −0.87 (−0.98 to −0.77) at 2 years, −0.88 (−1.03 to −0.74) at 10 years
- P = 0.13
TSH SDS, 10-year GH study (n=240) · 2 to 10 years
- TSH SDS decreased from −0.35 (−0.50 to −0.21) at 2 years to −0.68 (−0.84 to −0.53) at 10 years
- P < 0.001
Original publication
Thyroid hormone levels in children with Prader–Willi syndrome: a randomized controlled growth hormone trial and 10-year growth hormone study. Eur J Endocrinol. Published 25 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →